Everything
your lab fears about congressional action to reinstitute patient
co-insurance for Medicare lab testing may come true during 2012.
And that’s not the worst of it.
Even
as you read this, Congress is debating other equally damaging
proposals to substantially reduce reimbursement for laboratory
testing. Experts predict that these budget debates could result
in painful cutbacks of lab-test fees.
To
help you guide your laboratory through these uncertain times,
The Dark Report and DarkDaily.com is hosting two experts
who will give you an insider’s understanding of what’s
unfolding inside the Beltway for 2012.
Alan
Mertz, President of the American Clinical Laboratory Association
(ACLA) has been on the front lines educating Congress and policy-makers
about the value of laboratory testing. Get his perspective on
these issues when you register for a special audio conference,
“Washington Puts Lab-Test Cost-Cutting on the Table
for 2012: Devastating Fee Cuts Plus Other Congressional Proposals
and How Your Lab Can Prevent Them,” held on Wednesday,
October 26, 2011.
Mertz
will be joined by Peter Kazon, Senior Counsel in the Washington
D.C. office of Alston & Bird. Kazon has been front and center
in many of the most important legislative battles involving the
lab-testing industry in recent years.
Together,
these two experts will give you unprecedented access to how the
political process really works and why this session of Congress
may be the most financially destructive for clinical labs and
anatomic pathology groups.
You’ll
hear about the “big-three” threats to lab-test reimbursement
winding their way through Congress:
Why
reinstatement of the 20% Medicare patient lab-test co-pay/co-insurance
requirement could pass in this Congress.
MedPAC’s recommendation, made last month, that Congress
hack $11 billion out of lab-testing funding over the next 10
years. Where will that money go? To boost primary-care physician
payment levels.
How the 12-member, bipartisan congressional super committee
created by last summer’s debt-limit legislation is making
its own plans to cut lab-test reimbursement—without public
hearings. Their lab-specific proposals would produce up to $24
billion in savings over the next decade.
And
there’s more! As Medicare officials and congressional committees
assess coverage guidelines, this year they have extra motivation
to cut healthcare spending. In addition, Congress could legislate
more restrictive guidelines on when and how physicians can use
new molecular CPT codes and how labs will be reimbursed for them.
If
all this doesn’t scare you, it should. This is not “business
as usual” in Washington these days. Each of these threats
to the existing level of lab-test reimbursement is in active discussion
somewhere in the executive and legislative branches.
Join
us for this “must-attend” event that will provide
you with the information you need to guide your laboratory through
these uncharted waters.
You
and your colleagues still have time to educate your senators and
representatives about these issues. Register today and learn how
you can educate these officials and what steps your laboratory
can take to go on the record about the negative impact these proposals
will have on patient care.
Whether
you’re a lab administrator, pathologist, or industry consultant,
you need the most current information on proposed lab-testing
industry legislation, how it could impact your lab and the possible
strategies to keep Medicare co-pay legislation from becoming a
reality.
Order
today to guarantee your place at this essential learning session.
And remember that your entire management team can learn and participate
when you register.
THE
DARK REPORT AUDIO CONFERENCE AT A GLANCE
COST: $245 per digital recording
TO ORDER NOW:Click
here or call 1-800-560-6363 toll-free
For
one low price—just $245—you and your entire
team can take part in this fast-paced, insightful audio conference.
Best of all, you'll be able to connect personally with either
of the panelists when we open up the phone lines for live Q&A.
Here's just some of what you’ll learn during this in-depth
90-minute conference:
The
latest Medicare lab cost-sharing proposals being considered
by Congress and what they could mean for your lab.
The
potential impact of lab co-pays or co-insurance on laboratories
and Medicare beneficiaries.
Why lab co-insurance is now being considered when it's been
rejected so many times in the past.
Who MedPac is and why they're recommending major lab-test fee
reductions.
The primary arguments against the 20% copay proposal.
What your lab can do to educate Congress and stop it from passing
legislation that imposes lab co-insurance and reimbursement
cuts.
Other proposed regulatory action, including the possible elimination
of code stacking.
The potential for FDA regulation of lab-developed tests.
…and
much more!
How
to ORDER:
1. Online
2. Call toll free: 800-560-6363.
Your
audio conference registration includes:
Downloadable
PowerPoint presentations from our speakers
A
full transcript emailed to you soon after the conference
ORDER
Now!Or for more
information, call us toll-free at 800-560-6363.
Distinguished
Presenters:
Peter
Kazon is a Senior Counsel in the Washington
D.C. office of Alston & Bird. He advises laboratories,
diagnostic companies and companies with new technologies
on regulatory and compliance matters, including approval
and clearance, coverage, coding, and reimbursement issues.
He serves as outside counsel to the American Clinical
Laboratory Association. Mr. Kazon received his BA, magna
cum laude, from Tufts University and earned his JD from
Temple University.
Alan
Mertz has been President of ACLA since 2003.
He has overseen tripling of ACLA’s membership;
greater visibility of ACLA in Congress and the Administration;
expansion of ACLA membership services, meetings and
programs; and a series of key advocacy successes. From
1998-2003, Mr. Mertz was Executive Vice President and
Acting President of the Healthcare Leadership Council
(HLC), and from 1980 to 1998 served in three senior
staff positions in the House and Senate. He was selected
as a John C. Stennis Congressional Fellow in 1996, taught
as an adjunct professor at George Washington University
from 1997-1999, and is a lecturer at American University
in Washington, D.C. Mr. Mertz holds a master’s
degree in American politics from American University
and a BA in government from Monmouth College.
ACCENT®
Continuing Education Credit
The American Association of Clinical Chemistry (AACC) designates
this program for a maximum of 1.5 ACCENT® credit hours towards
the AACC Clinical Chemist’s Recognition Award. AACC is an
approved provider of continuing education for clinical laboratory
scientists in the states of California, Florida, Louisiana, Montana,
Nevada, North Dakota, Rhode Island, and West Virginia.